Literature DB >> 202827

Endocrine profile of ergot alkaloids.

E E Můller, A E Panerai, D Cocchi, P Mantegazza.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 202827     DOI: 10.1016/0024-3205(77)90231-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  8 in total

1.  Treatment of pituitary tumors: history.

Authors:  Gaya Thanabalasingham; Niki Karavitaki; Simon Cudlip; John A H Wass
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 2.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Treatment of Schizophrenia with ergot derivatives.

Authors:  C A Tamminga; M H Schaffer
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

Review 4.  Pharmacology of bromocriptine in health and disease.

Authors:  A E Mehta; G Tolis
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

Review 5.  Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

6.  Effect of two antiserotoninergic drugs, methysergide and metergoline, on gastric acid secretion and gastrin release in healthy man.

Authors:  R Caldara; C Ferrari; C Barbieri; M Romussi; P Rampini; P Telloli
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

7.  Extensive ultrastructural changes in rat mammotrophs following administration of the dopamine agonist ergocristine-reflecting inhibition of prolactin release.

Authors:  C W Reifel; S H Shin; R A Leather
Journal:  Cell Tissue Res       Date:  1983       Impact factor: 5.249

8.  Evidence for an irreversible interaction of bromocryptine with central dopamine receptors.

Authors:  M J Bannon; A A Grace; B S Bunney; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.